Drugs / NKG2D CAR-NK
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05248048 | Sep 2021 → Oct 2022 | colorectal cancer | The Third Affiliated Hospital of Guangzhou Medical University | Unknown | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT05213195 | Dec 2021 → Dec 2024 | colorectal cancer | Zhejiang University | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06856278 | Feb 2025 → Dec 2028 expected | thyroid gland undifferentiated (anaplastic) carcinoma | Zhejiang Provincial People's Hospital | Not yet recruiting | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT05776355 | Mar 2023 → Apr 2024 | ovarian carcinoma | Hangzhou Cheetah Cell Therapeutics Co., Ltd | Unknown | No outcome recorded |
| — | NCT05734898 | Mar 2023 → Apr 2024 | acute myeloid leukemia | Zhejiang University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NKG2D CAR-NK | “NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer” NCT05248048 ↗ |
| Modality | Cell therapy | “NKG2D CAR-NK Cell Therapy” NCT05213195 ↗ |
| Route | Other | “intra-peritoneal infusion” NCT05213195 ↗ |